1.
|
Phase: Phase IV
Type: Prevention
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 562, NCT00847912
|
|
2.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 16 to 45
Sponsor: Other
Protocol IDs: P50DA016511, NCT00664755
|
|
3.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2009-P-000444, NCT00907218
|
|
4.
|
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
|
|
5.
|
Phase: Phase III, Phase II
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: 2003-1024, 1R01DA017073, NCT00507728
|
|
6.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 40 to 80
Sponsor: NCI
Protocol IDs: UARIZ-00-0430-01, 00-0430-01, UARIZ-HSC-00142, NCT00078897
|
|
7.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 35 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3
|
|
8.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2003-0824, EPOC, NCT00402779
|
|
9.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111955, NCT00799825
|
|
10.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 30 to 75
Sponsor: Other
Protocol IDs: GD-10-08, NCT00808522
|
|
11.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 9 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_611, V503-002, NCT00943722
|
|
12.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 11 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_670, V503-005, NCT00988884
|
|
13.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Nabi-4514, NIH grant # 1 RC2 DA028837-01, NCT00836199
|
|
14.
|
Phase: Phase III
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: NHLBI
Protocol IDs: 625, HL087643-01A2, NCT00843505
|
|
15.
|
Phase: Phase III
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: R21 AT003669-01, R21AT003669-01, NCT00492310
|
|
16.
|
Phase: Phase III
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Pro00013846, NCT00894166
|
|
17.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 55 and over
Sponsor: NCI, Other
Protocol IDs: CAPS08-15024, NCT01052051
|
|
18.
|
Phase: Phase II, Phase I
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2003-0811, NCT00346502
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0405-2006, NCT00400374
|
|
20.
|
Phase: Phase II, Phase I
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 0596-2004, NCT00314262
|
|
21.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: 21 to 48
Sponsor: NCI
Protocol IDs: CHNMC-IRB-02164, NCT00080756
|
|
22.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: Postmenopausal
Sponsor: NCI
Protocol IDs: GUMC-2007-313, NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313
|
|
23.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 40
Sponsor: Other
Protocol IDs: 02-422, Army's HSRRB log no. A-10926, UTMB GCRC 533, DAMD17-01-1-0417, NIH NCRR GCRC M01 RR00073, NCT00204477
|
|
24.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 42
Sponsor: NCI, Other
Protocol IDs: 03-260, UTMB GCRC #635, NIH R01-CA95545, NIH NCRR GCRC M01 RR00073, NCT00204490
|
|
25.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0305-20, NCT00198081
|
